Vaxcyte Appoints New CMO and CLO, Narrows VAX-31 Pivotal Trial Data Timeline

Vaxcyte announced the appointment of a new Chief Medical Officer and Chief Legal Officer, strengthening its leadership team ahead of key clinical data. The company also narrowed its guidance for the topline data from its VAX-31 adult Phase 3 pivotal trial (OPUS-1), now expecting results by the end of October 2026.

Key Details

• Updated VAX-31 Guidance: Topline safety, tolerability, and immunogenicity data from the Phase 3 OPUS-1 trial is now expected by the end of October 2026, a refinement from the previous guidance of Q4 2026.
• Chief Medical Officer Appointed: Luis Jodar, Ph.D., former Senior Vice President and Chief Medical Officer for Vaccines at Pfizer with extensive experience on the Prevnar franchise, has been appointed as CMO.
• Chief Legal Officer Appointed: David McAvoy, J.D., former Executive Vice President and Chief Legal Officer at Teva Pharmaceutical Industries, has been appointed as CLO.
• Strategic Timing: These leadership appointments and the updated timeline come as Vaxcyte prepares for a planned Biologics License Application (BLA) submission and potential commercialization of VAX-31.